Prevail Therapeutics, the biotech company focused on developing therapies for the treatment of Parkinson’s Disease, has raised $50M in Series B funding from investors that include OrbiMed, RA Capital Management, Pontifax, Omega Funds, Adage Capital Management, EcoR1 Capital, AbbVie Biotech Ventures, Biotechnology Value Fund, Boxer Capital, and Surveyor Capital. Founded by Asa Abeliovich in 2017, Prevail Therapeutics has now raised a total of $125M in reported equity funding.